Health and Healthcare

All Health and Healthcare Articles

Newest first · Page 255

Are Teva Earnings Enough?

ThinkstockTeva Pharmaceutical Industries Limited (NYSE: TEVA) reported its second-quarter financial results Thursday before the markets opened. The company had $1.43 in earnings per share (EPS) on $5.0 billion in revenue compared to Thomson Reuters…

Chris Lange · 11 years ago

More Doctors Flee Private Practice

ThinkstockThe old style independent doctor has continued to disappear. Practicing in a hospital has become a better financial deal, as the costs of insurance rise, and the income from visits, and procedures falls. According…

Douglas A. McIntyre · 11 years ago

Is This a Turning Point For Unilife?

ThinkstockUnilife Corp. (NASDAQ: UNIS) announced the introduction of the Imperium platform of instant patch pumps for insulin. The platform is designed for supply to a select insulin partner or partners ready for filling and…

Chris Lange · 11 years ago

Should Gilead Really Be Rated Underperform?

ThinkstockMost analysts seem to be behind the growth that Gilead Sciences Inc. (NASDAQ: GILD) has seen, namely in its Hepatitis C vaccines (HCV) Harvoni and Solvaldi. For the most part the resulting analyst calls…

Chris Lange · 11 years ago

Who Really Won in the PDL and Ariad Royalty Deal?

ThinkstockThe solid performance of the healthcare sector over the past year has been enhanced by mergers and acquisitions, licensing, and other forms of deals in the sector. This most recent deal in the sector…

Chris Lange · 11 years ago

GC Aesthetics Sets Expected Price Range For IPO

ThinkstockGC Aesthetics PLC filed an amended F-1 form with the Securities and Exchange Commission (SEC) for its initial public offering (IPO). The expected price range for the offering was given as $13 to $15…

Chris Lange · 11 years ago

Humana Posts 2Q Earnings Beat

ThinkstockHumana Inc. (NYSE: HUM) reported its second-quarter financial results Wednesday before the markets opened. The company had $1.67 in earnings per share (EPS) on $13.73 billion in revenue compared to Thomson Reuters consensus estimates…

Chris Lange · 11 years ago

Anthem Posts Strong Second Quarter Beat

ThinkstockAnthem, Inc. (NYSE: ANTM) reported its second-quarter financial results Wednesday before the markets opened. The company had $3.10 in earnings per share (EPS) on $19.76 billion in revenue compared to Thomson Reuters consensus estimates…

Chris Lange · 11 years ago

Dermira Files For Secondary Offering

ThinkstockDermira, Inc. (NASDAQ: DERM) filed an S-1 form with the Securities and Exchange Commission (SEC) for a secondary offering. There were no terms given in this initial filing but the proposed maximum price is…

Chris Lange · 11 years ago

Gilead Tops Estimates in 2Q

courtesy of Gilead SciencesGilead Sciences Inc. (NASDAQ: GILD) reported second-quarter financial results Tuesday after the markets closed. The biotech giant had $3.15 in earnings per share (EPS) on $8.2 billion in revenue compared to…

Chris Lange · 11 years ago

NantKwest Enters the Market With a Bang

ThinkstockNantKwest (NASDAQ: NK) entered the market Tuesday with its initial public offering (IPO). The stock priced early Tuesday morning at $25 per share coming over the top of the expected price range of $20…

Chris Lange · 11 years ago

Was the Immunomedics Sell-Off Too Extreme?

ThinkstockBelgian pharmaceutical group UCB announced Tuesday morning that its phase 3 trial for lupus treatment epratuzumab failed to produce statistically significant results in both dosages tested in Systemic Lupus Erythematosus (SLE). The developer said…

Chris Lange · 11 years ago

Are Merck Earnings Enough?

ThinkstockMerck & Co. Inc. (NYSE: MRK) reported its second-quarter financial results Tuesday before the markets opened. The pharmaceutical giant had $0.86 in earnings per share (EPS) on $9.8 billion in revenue compared to Thomson…

Chris Lange · 11 years ago

Can Nymox Sustain This Massive Rally?

ThinkstockNymox Pharmaceutical Corp. (NASDAQ: NYMX) was one of the best performers on Monday despite a down day in the market. And Nymox is absolutely dominating in 2015 in terms of its performance, as of Friday’s…

Chris Lange · 11 years ago